Neurogene Inc. Files Q1 2025 10-Q
Ticker: NGNE · Form: 10-Q · Filed: May 9, 2025 · CIK: 1404644
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financial-reporting
TL;DR
Neurogene Inc. 10-Q filed. Q1 2025 update.
AI Summary
Neurogene Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Neoleukin Therapeutics, Inc., is in the pharmaceutical preparations industry. Its business address is 535 W 24th Street, 5th Floor, New York, NY 10011.
Why It Matters
This filing provides an update on Neurogene Inc.'s financial performance and operational status for the first quarter of 2025, which is crucial for investors and stakeholders to assess the company's trajectory.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing financial and operational updates, not indicating immediate significant risks.
Key Players & Entities
- Neurogene Inc. (company) — Filer
- Neoleukin Therapeutics, Inc. (company) — Former company name
- 20250331 (date) — Period of report
- 20250509 (date) — Filing date
- 535 W 24TH STREET (address) — Business street address
- NEW YORK (location) — Business city
FAQ
What was Neurogene Inc.'s former company name?
Neurogene Inc.'s former company name was Neoleukin Therapeutics, Inc., with a date of name change on 20190812.
What is Neurogene Inc.'s Standard Industrial Classification code?
Neurogene Inc.'s Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
What is the filing date of this 10-Q report?
The filing date of this 10-Q report is 20250509.
What is the fiscal year end for Neurogene Inc.?
Neurogene Inc.'s fiscal year end is December 31 (1231).
What is the business address of Neurogene Inc.?
Neurogene Inc.'s business address is 535 W 24TH STREET, 5TH FLOOR, NEW YORK, NY 10011.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Neurogene Inc. (NGNE).